
Research from a team led by Brian Piening, PhD, Program Director for Providence Genomics that included colleagues from across Providence as well as collaborators at Illumina and Microsoft demonstrated that a majority (67%) of patients tested with the ProvSeq-Solid Tumor Comprehensive Genomic Profiling (CPG) test were candidates for guideline-recommended precision cancer therapy and those treated with these therapies showed significant improvements in overall survival rate versus chemotherapy. Read More
Learn more























